Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG:

vepdegestrant (ARV-471)

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Company:

Arvinas, Pfizer

Drug class:

Selective estrogen receptor α degrader

Related drugs:

‹

›

ER positive	HER2 Negative Breast Cancer	ER positive	HER2 Negative Breast Cancer	ARV-471 Sensitive: B - Late Trials ARV-471 Sensitive : B	ARV-471 Sensitive: B - Late Trials ARV-471 Sensitive : B
ER positive + ESR1 mutation	HER2 Negative Breast Cancer	ER positive + ESR1 mutation	HER2 Negative Breast Cancer	ARV-471 Sensitive: C3 – Early Trials ARV-471 Sensitive : C3	ARV-471 Sensitive: C3 – Early Trials ARV-471 Sensitive : C3
ER positive	HER2 Negative Breast Cancer	ER positive	HER2 Negative Breast Cancer	palbociclib + ARV-471 Sensitive: C3 – Early Trials palbociclib + ARV-471 Sensitive : C3	palbociclib + ARV-471 Sensitive: C3 – Early Trials palbociclib + ARV-471 Sensitive : C3
ER underexpression + ER Y537S	Breast Cancer	ER underexpression + ER Y537S	Breast Cancer	ARV-471 Sensitive: D – Preclinical ARV-471 Sensitive : D	ARV-471 Sensitive: D – Preclinical ARV-471 Sensitive : D
ER underexpression	Breast Cancer	ER underexpression	Breast Cancer	ARV-471 Sensitive: D – Preclinical ARV-471 Sensitive : D	ARV-471 Sensitive: D – Preclinical ARV-471 Sensitive : D